CLINICAL_TRIALS
trial_result
· 2017-03-09
Clinical Trial Update: Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma [Phase 2]
Summary
A Phase 2 trial evaluating a combination of BRAF-targeted therapy and immunotherapy for melanoma was terminated, with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Massachusetts General Hospital | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2017-03-09